MAIA Biotechnology, Inc.

Healthcare · Biotechnology · United States

Last price 1.14 USD (Oct 30, 2026, 10:29 AM EDT) · Market cap 69.34M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.